Key Releases are ad hoc announcements pursuant to SIX Swiss Exchange Article 53 Listing Rules.
Header
News archive
News Archive Navigation
icon
News Archive Navigation Language
Language Preferences
Showing 1817 results
April 2019
-
Media ReleaseEurope-Africa partnership spearheads development of next-generation antimalarial drugThe European & Developing Countries Clinical Trials Partnership (EDCTP) grants EUR 10 million over five years to "WANECAM 2" a unique collaboration between antimalarial drug researchers in…
-
In The NewsHow to be a boss in an unbossed companyIn this interview, Novartis CEO Vas Narasimhan sits down with CNNMoney Switzerland’s Urs Gredig and shares why he thinks innovation should come from the bottom and how wearing jeans and no…
-
Media ReleaseSandoz drives differentiated portfolio with deal to commercialize new treatment for Opioid-Induced Constipation in key European countriesAgreement with Shionogi to commercialize Rizmoic® (naldemedine) in Germany, UK and Netherlands, plus right of first refusal for certain other European markets Rizmoic® is an innovative medicine…
-
Counting on combos for complex liver diseases
The best treatment for multifaceted diseases like NASH may be combinations of drugs.
-
Featured NewsAlcon becomes a separately traded standalone company
On April 9, 2019 Alcon becomes a separately traded company. Novartis and Alcon are now positioned to capitalize on significant growth opportunities and focus resources on their respective businesses and strategic priorities.
-
Media ReleaseNovartis continues transformation into a leading medicines company with completion of the Alcon spin-offNovartis positioned for sustained growth, including plans to improve Innovative Medicines core margins into mid-30s by 2022 Novartis has a catalyst-rich pipeline with 10 potential blockbuster…
-
Bringing gene therapy into focus
Dr. Botond Roska says we should keep our eyes on gene therapy.
-
Media ReleaseNovartis updates on the migraine collaboration with AmgenBasel, April 4, 2019 - Novartis announced today that there is a legal dispute with Amgen regarding the collaboration agreements in the field of migraine. On April 2, 2019, Amgen issued a notice of…
-
In The NewsMedicines and transformative effectIn this Bloomberg interview, Vas Narasimhan, CEO of Novartis shares his thoughts on how medicines can have a transformative effect.
-
Media ReleaseSandoz resubmits biosimilar pegfilgrastim application to US FDASandoz pursues US approval for biosimilar pegfilgrastim, a long-acting version of supportive oncology medicine filgrastim Pegfilgrastim is used to reduce the incidence of neutropenia, one…
-
Featured NewsSustaining the momentum toward universal health coverage in Africa
The first pan-African Novartis Social Business stakeholder dialogue took place in Kampala, Uganda, on March 20, 2019.
-
Media ReleaseNovartis first-in-class Cosentyx® approved in China for psoriasis patientsChina Health Authority NMPA approved Cosentyx® (secukinumab) for moderate-to-severe plaque psoriasis in adult patients who are candidates for systemic therapy or phototherapy Cosentyx is…
Pagination
- ‹ Previous page
- 1
- …
- 72
- 73
- 74
- 75
- 76
- 77
- 78
- …
- 152
- › Next page